Literature DB >> 7107972

Importance of protein binding for the interpretation of serum or plasma drug concentrations.

D J Greenblatt, E M Sellers, J Koch-Weser.   

Abstract

The extent of drug binding to plasma protein does not influence the concentration of unbound drug in plasma at steady state but does influence the interpretation of total drug concentrations. An increase in free fraction (reduction in the extent of binding) decreases the therapeutic and toxic ranges for total drug concentrations. Conversely, a reduction in free fraction (increase in the extent of binding) increases these ranges. Laboratories generally measure total rather than unbound drug concentrations, and clinicians must use caution in interpreting these total drug concentrations in clinical situations where the extent of binding of extensively bound drugs may be altered. Free drug serum or plasma concentrations are inherently more reliable indices of the intensity of drug action than are total concentrations. Methodology for routine measurement of free concentration is becoming available and should ultimately be utilized for therapeutic monitoring of drugs that are highly bound to protein.

Mesh:

Substances:

Year:  1982        PMID: 7107972     DOI: 10.1002/j.1552-4604.1982.tb02671.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  27 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

2.  Prescribing drugs for the elderly: reaching therapeutic goals.

Authors:  H G Preiksaitis; M Gordon
Journal:  Can Fam Physician       Date:  1986-12       Impact factor: 3.275

Review 3.  Choice and use of newer anticonvulsant drugs in older patients.

Authors:  L J Willmore
Journal:  Drugs Aging       Date:  2000-12       Impact factor: 3.923

4.  Effect of a protein binding change on unbound and total plasma concentrations for drugs of intermediate hepatic extraction.

Authors:  R H Smallwood; G W Mihaly; R A Smallwood; D J Morgan
Journal:  J Pharmacokinet Biopharm       Date:  1988-10

5.  Steady-state kinetics of imipramine in transgenic mice with elevated serum AAG levels.

Authors:  J W Holladay; M J Dewey; S D Yoo
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

6.  The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin.

Authors:  M Oellerich; H Müller-Vahl
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

7.  Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin.

Authors:  Pankaj K Sethi; Catherine A White; Brian S Cummings; Ronald N Hines; Srinivasa Muralidhara; James V Bruckner
Journal:  Pediatr Res       Date:  2015-11-16       Impact factor: 3.756

8.  Variability of the serum protein binding of theophylline in patients with asthma and cystic fibrosis.

Authors:  J Blanchard; S Harvey; W J Morgan
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

9.  Decreased serum protein binding of diazepam and its major metabolite in the neonate during the first postnatal week relate to increased free fatty acid levels.

Authors:  H Nau; W Luck; W Kuhnz
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

10.  Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity.

Authors:  R M Arendt; D J Greenblatt; D C Liebisch; M D Luu; S M Paul
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.